DEF: NovaBay Pivots with New Investor, Massive Dilution Ahead

NovaBay Pharmaceuticals announces a strategic pivot with a new $6.0 million investment from David E. Lazar, leading to significant shareholder dilution and a planned reverse stock split.

Summary

• NovaBay Pharmaceuticals is undergoing a major strategic shift, having divested its Avenova, wound care, and DERMAdoctor businesses, significantly reducing assets and revenue.
• The Board opted for an investment transaction over a previously approved voluntary liquidation, aiming to maximize shareholder value through a new strategic direction.
• David E. Lazar is investing up to $6.0 million, with $3.85 million already received in the First Closing for Series D Preferred Stock, and an additional $2.15 million expected in the Final Closing for Series E Preferred Stock.
• Upon full conversion of Series D and E Preferred Stock, Mr. Lazar will hold approximately 120.0 million shares of Common Stock, representing about 95% of the company's fully diluted outstanding shares.
• A special cash dividend of $0.80 per share was declared on August 26, 2025, payable September 29, 2025, to stockholders of record on September 15, 2025, with preferred stockholders not participating.
• The company plans to pursue a 'Post-Investment Transaction' to acquire an operating company, aiming for future growth.
• Stockholders will vote on several proposals at the October 16, 2025 Annual Meeting, including director elections, executive compensation, ratification of auditors, approval for the conversion of preferred stock (Proposal Five), an increase in shares for the 2017 Omnibus Incentive Plan, equity consideration for resigning directors, a reverse stock split (ratio 1-for-2 to 1-for-10), and increases in authorized common and preferred stock.
• Mr. Lazar has been appointed CEO and a director, and will have contractual rights to be appointed Chair of the Board and nominate additional directors upon certain conditions being met.
• Existing voting commitments from Remaining Warrant Holders (12.3% voting power) and Poplar Entities (17.5% outstanding Common Stock) ensure approximately 29.8% of voting power will support all proposals.

Sentiment

Score: 4

Explanation: The sentiment is cautiously negative for existing shareholders due to the extreme dilution (95%) and loss of control to a new investor. While the new investment provides a lifeline and a strategic pivot, the success of the undefined 'Post-Investment Transaction' is highly speculative. The special dividend offers a small immediate return, but the long-term value proposition for current shareholders is uncertain and dependent on the new management's ability to execute a successful, high-risk turnaround.

Positives

• Secured a $6.0 million investment from David E. Lazar, providing capital for future operations and strategic initiatives.
• Declared a one-time special cash dividend of $0.80 per share for existing common stockholders, offering immediate return.
• The company is pursuing a 'Post-Investment Transaction' to acquire a new operating business, signaling a clear path for future growth after divesting non-core assets.
• New leadership with David E. Lazar as CEO brings experience in transformative transactions and publicly-traded companies.
• The Board has established a Special Transaction Committee to provide independent oversight of the Investment Transaction and Special Dividend.

Negatives

• Existing common stockholders will experience significant dilution, with Mr. Lazar's preferred stock converting into approximately 95% of the fully diluted common stock.
• Mr. Lazar will gain effective voting control over the company, potentially limiting the influence of other shareholders.
• The company's assets, operations, and revenue have been significantly reduced following recent divestitures.
• The success of the new strategic direction is highly dependent on identifying and successfully consummating an undefined 'Post-Investment Transaction'.
• Failure to obtain stockholder approval for Proposal Five (Conversion Approval) would prevent the Final Closing ($2.15 million investment) and hinder Mr. Lazar's Board rights and the pursuit of a Post-Investment Transaction.
• The proposed Reverse Stock Split may not proportionately increase the stock price, could decrease overall market capitalization, and potentially reduce liquidity.

Risks

• Stockholders will experience significant dilution (approximately 95%) upon the full conversion of Series D and Series E Preferred Stock into Common Stock.
• Mr. Lazar will gain effective voting control over the company, potentially influencing all matters presented to stockholders.
• Failure to obtain Conversion Approval (Proposal Five) will prevent the Final Closing and the additional $2.15 million investment, hindering operations and the pursuit of a Post-Investment Transaction.
• The company may fail to realize the anticipated benefits of the Investment Transaction if a suitable Post-Investment Transaction is not identified or successfully consummated.
• Pursuing a Post-Investment Transaction may require additional capital, leading to further equity issuance and potential dilution for stockholders.
• Significant changes to the Board and management team are expected, which could alter the company's direction and priorities.
• Failure to obtain stockholder approval for increasing authorized common and preferred stock (Proposals Nine and Ten) could limit future financing and business development activities.
• The market price of Common Stock may decline due to the substantial dilutive impact of the preferred stock conversion or failure to achieve strategic benefits.
• There is a risk of delisting from NYSE American if the company fails to regain or maintain compliance with listing requirements, such as minimum share price.
• A Reverse Stock Split may not increase the stock price proportionately, could decrease overall market capitalization, or reduce trading liquidity.
• The Reverse Stock Split may result in some stockholders owning 'odd lots' (less than 100 shares), potentially leading to higher transaction costs.
• The increased number of authorized but unissued shares post-Reverse Stock Split and from Proposals Nine and Ten could be used for future issuances, causing further dilution without additional stockholder approval.
• Mr. Lazar's Securities Purchase Rights allow him to assign or transfer his preferred stock and conversion rights to an unknown third party, who would then acquire significant control.

Future Outlook

The company intends to use net proceeds from the Investment Transaction to pursue a 'Post-Investment Transaction,' involving the investment in and/or acquisition of an operating, going concern, and solvent company. This is expected to provide a future growth opportunity for the company and its stockholders by combining with a new operating and revenue-generating entity. The Board believes this path is a better opportunity to maximize value than the previously approved dissolution. The company also aims to maintain NYSE American listing compliance through a potential reverse stock split and increased authorized shares to facilitate future capital raises and strategic transactions.

Management Comments

• The Board unanimously determined that pursuing the Investment Transaction, providing for a Special Dividend and the opportunity for a Post-Investment Transaction, instead of pursuing the Dissolution at this time, is a better opportunity to maximize the value of the Company for stockholders and is in the best interest of the Company and its stockholders.
• The Board believes that until the Final Closing, the Board is best served by continuing to separate the roles of Chair and Chief Executive Officer to enhance both the independence of the Board and its effectiveness in discharging its responsibilities.
• After the Final Closing and as a result of the Investment Transaction, the Board believes that NovaBay will be best served by combining the roles of Chair and Chief Executive Officer in order for Mr. Lazar to lead the Company in pursuing a Post-Investment Transaction.
• The Board expects that the Reverse Stock Split will increase the market price of our Common Stock, which will improve the marketability and liquidity of our Common Stock and will encourage interest and trading in our Common Stock.

Industry Context

NovaBay Pharmaceuticals is undergoing a significant transformation, moving away from its historical focus on eyecare, wound care, and skin care products after divesting substantially all of its revenue-generating assets. This strategic pivot, driven by a new lead investor, suggests a shift towards a new, currently undefined, operating business. This move is indicative of a company seeking to reinvent itself after previous business lines proved unsustainable or less profitable, a trend seen in the pharmaceutical and biotech sectors where companies may pivot to new therapeutic areas or business models following asset sales or clinical trial outcomes. The reliance on a new investor to fund this pivot and the subsequent search for a 'Target Company' positions NovaBay as a 'shell' or 'blank check' company in transition, a common strategy for companies seeking to re-enter a growth phase through acquisition rather than organic development in their former core areas.

Comparison to Industry Standards

• The company's strategic pivot, involving the divestiture of its core assets (Avenova, wound care, DERMAdoctor) and seeking a 'Post-Investment Transaction' to acquire a new operating business, is a significant departure from its historical pharmaceutical/dermatology focus. This resembles a 'reverse merger' or 'special purpose acquisition company (SPAC)' type of transaction, where a publicly traded entity acquires a private operating company to bring it public or give it a new platform.
• Direct comparison to industry standards for its *new* business is not possible as the 'Target Company' for the Post-Investment Transaction is currently undefined. However, the prior divestitures suggest that its former product lines (e.g., Avenova in eyecare) may not have met competitive or market expectations, leading to the strategic shift.
• The proposed 95% dilution to existing shareholders in favor of a new lead investor (David E. Lazar) is an extreme level of dilution, far exceeding typical capital raises or strategic investments in established companies. This indicates a distressed situation where the company's prior value was significantly impaired, and the new investment is essentially a recapitalization and change of control.
• The declaration of a $0.80 per share special dividend for common stockholders, while positive, must be viewed in the context of the impending 95% dilution. It serves as a partial return of capital to existing shareholders before their ownership is drastically reduced, rather than a sign of robust ongoing profitability or growth.
• The proposed reverse stock split (1-for-2 to 1-for-10) is a common tactic for companies facing potential delisting due to low share price, aiming to meet exchange minimums. This is a reactive measure, not typically indicative of strong underlying business performance, and has a mixed track record in terms of long-term stock price appreciation for comparable small-cap companies.

Management Changes

Corporate Governance

Related Party Transactions

• Investment Transaction: David E. Lazar, who is now CEO and a director, is investing up to $6.0 million in the company through preferred stock, which will give him approximately 95% ownership upon full conversion.
• Employment Agreements: New employment agreements were entered into with Justin M. Hall (former CEO, now VP of Business Development, General Counsel, Corporate Secretary) and Tommy Law (CFO and Treasurer) in connection with the First Closing.
• Release Agreements: Entered into with Justin M. Hall and five Resigning Non-Employee Directors (Dr. Paul E. Freiman, Ms. Julie Garlikov, Ms. Swan Sit, Mr. Mijia (Bob) Wu, Mr. Yongxiang (Sean) Zheng) for their resignations, involving cash settlements for Mr. Hall and equity consideration for the non-employee directors.
• Series F Agreements: Entered into with three largest remaining holders of Series F Warrants (Anson Investments Master Fund LP, Hudson Bay Capital Management LP, Armistice Capital, LLC), involving issuance of Series F Preferred Stock and cash payments of $175,000 each, with voting commitments.
• Voting Agreement: Entered into with Jad Fakhry and Poplar Entities (owning ~17.5% of Common Stock) for voting commitments in favor of all proposals and a standstill provision.
• Mr. Lazar's Investor Rights: Includes contractual rights to recommend directors, be appointed Chair, nominate additional directors, and participate in future financing transactions.

Stakeholder Impact

• Shareholders: Existing common stockholders will experience significant dilution (approximately 95%) and a substantial reduction in voting power due to the conversion of preferred stock by the new investor. They will receive a one-time special cash dividend of $0.80 per share.
• New Investor (David E. Lazar): Will gain effective voting control (approximately 95% ownership) and significant influence over the company's strategic direction and management.
• Employees: Changes in executive management (new CEO, new CFO, former CEO in new role) and potential future changes related to a Post-Investment Transaction could impact employee roles and organizational structure.
• Directors: Five non-employee directors and the former CEO will resign from the Board upon the 'Resignation Event', receiving equity or cash consideration for their departure. New directors nominated by Mr. Lazar are expected to join.
• Creditors: The new investment provides capital that will be used for operations and to satisfy certain obligations, potentially improving the company's financial stability in the short term, but the long-term impact depends on the success of the new strategic direction.
• Customers/Suppliers: The divestiture of core product lines means a significant change in the company's offerings and operations, which will impact existing customer and supplier relationships. The future impact depends on the nature of the 'Post-Investment Transaction'.

Next Steps

• Hold the 2025 Annual Meeting of Stockholders on October 16, 2025, to vote on 12 proposals.
• If Proposal Five (Conversion Approval) is approved, proceed with the Final Closing of the Investment Transaction by the end of the fourth quarter of 2025, receiving an additional $2.15 million.
• Upon the Resignation Event (including Conversion Approval, Final Closing, appointment of new directors, Special Dividend paid, and Proposal Seven approved), Mr. Hall and five non-employee directors will resign from the Board.
• After the Final Closing and Board approval, identify and pursue a 'Post-Investment Transaction' to acquire an operating company.
• If Proposal Eight (Reverse Stock Split) is approved, the Board will determine the specific ratio (1-for-2 to 1-for-10) and timing to effectuate the split.
• If Proposals Nine and Ten (increase authorized shares) are approved, file the respective Certificates of Amendment with the Delaware Secretary of State.
• File a Registration Statement on Form S-8 for the 2017 Omnibus Plan shares after Proposal Six approval.
• If Conversion Approval and other Purchase Agreement-related proposals are not approved at the Annual Meeting, call a Second Meeting within 70 days.

Key Dates

Recommendation

The filing details a transformative event for NovaBay, effectively a recapitalization and change of control. Existing common shareholders face an extreme dilution of approximately 95% of their ownership and voting power to a new investor, David E. Lazar. While a special cash dividend of $0.80 per share is offered, this is a small return compared to the loss of proportional ownership. The company's future is now entirely dependent on an undefined 'Post-Investment Transaction' and the new management's ability to execute a successful pivot. For a seasoned investor, the massive dilution and the highly speculative nature of the future business, coupled with the loss of control, make this a strong 'sell' for existing common shareholders who are not explicitly buying into the new, high-risk venture. The risk-reward profile for remaining shareholders is significantly altered and highly uncertain.

Keywords

NovaBay Pharmaceuticals, NBY, SEC filing, DEF 14A, Proxy Statement, Investment Transaction, David E. Lazar, Series D Preferred Stock, Series E Preferred Stock, Stockholder Dilution, Reverse Stock Split, Special Dividend, Post-Investment Transaction, Corporate Governance, Authorized Shares, Executive Compensation, NYSE American, Strategic Pivot, Pharmaceuticals